Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(27 sites)
India
Omega Cancer Hospitals, Visakhapatnam, Andhra Pradesh Post Graduate Institute of Medical Education & Research,, Chandigarh, Chandigarh Cellcure Care Cancer Pvt Ltd, Ahmedabad, Gujarat HCC Happiness Care and Cure Multispeciality Hospital, Ahmedabad, Gujarat Shankus Hospital Pvt. Ltd., Ahmedabad, Gujarat Unique Hospital, Surat, Gujarat Kiran Multi Speciality Hospital, Surat, Gujarat Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana Super Specialty Hospital (G.M.C) Srinagar, Srinagar, Jammu and Kashmir KLES Dr Prabhakar Kore Hospital and MRC, Belagavi, Karnataka Amrita Institute of Medical Sciences (AIMS), Kochi, Kerala Sujan Surgical Cancer Hospital and Amravati Cancer Foundation, Amravati, Maharashtra Dr. Bafna's Star Superspeciality Clinic & Hospital, Kolhāpur, Maharashtra Kolhapur Cancer Centre, Kolhāpur, Maharashtra Mumbai Onco Care Centre, Mumbai, Maharashtra All India Institute of Medical Sciences, Nagpur, Maharashtra HCG Manavata Cancer Centre, Nashik, Maharashtra Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra Sahyadri Super Specialty Hospital, Pune, Maharashtra Sushrut Hospital, Pune, Maharashtra Armed Forces Medical College, Pune, Maharashtra Sunact Cancer Institute Pvt. Ltd, Thane, Maharashtra Rajiv Gandhi Cancer Institute and Research Centre, Delhi, National Capital Territory of Delhi All India Institute of Medical Sciences, Delhi, New Delhi Sparsh Hospital and Critical Care (P) Ltd., Bhubaneswar, Odisha MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, Telangana Tata Medical Center, Kolkata, West Bengal